Palatin Technologies, Inc. (Palatin), is a biopharmaceutical company. Palatin is focused on developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Palatin product candidates are targeted receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. The melanocortin receptor (MCr) system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. The natriuretic peptide receptor (NPR) system regulates cardiovascular functions and tissue homeostasis, and therapeutic agents modulating this system have potential to treat cardiovascular and fibrotic diseases. Palatin lead product includes Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Its other product line includes PL9643 for dry eye disease and anti-inflammatory ocular indications and Oral PL8177 for inflammatory bowel diseases.
Sales per Business
Melanocortin and Natriuretic Peptide Receptor Systems